Weight Loss & MetabolicGrade B
AOD-9604
A modified fragment of human growth hormone (176-191) marketed for fat loss, with human trials that failed to separate from placebo.
- Regulatory status
- Not approved
- Half-life
- ~30 minutes
- Route
- Subcutaneous or oral (research)
- Evidence
- Limited human trials or approved outside the US
Mechanism of action
Proposed stimulation of lipolysis and inhibition of lipogenesis without affecting IGF-1 or blood glucose.
Studied and reported uses
- Claimed fat loss
- Investigated for osteoarthritis
Dosing information
Reported research use300 mcg daily, fasted
Ranges are reported from literature and clinical labeling for reference only. They are not a dosing recommendation.
Side effects
- Generally well tolerated
- Injection-site irritation
Research evidence
Phase 2b
No significant weight loss vs placebo over 12 weeks.